Who is sponsoring NCT03481868?

NCT03481868 is sponsored by University Hospital, Clermont-Ferrand.

What drugs are being tested in NCT03481868?

Interventions in NCT03481868: Collection of blood and bone marrow.

What condition does NCT03481868 study?

NCT03481868 studies Chronic Myeloid Leukemia (CML), Chronic Phase.

Is NCT03481868 still recruiting?

NCT03481868 is currently recruiting now. Last updated 9 April 2024.

Last reviewed 2024-04-09 · How we verify

NCT03481868: EPIK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

Recruiting now NA Last updated 9 April 2024

What this trial tests

NA trial testing Collection of blood and bone marrow in Chronic Myeloid Leukemia (CML) in 160 participants. Currently enrolling.

Timeline

1 February 2018

Primary endpoint
1 May 2025

1 February 2026

Quick facts

Lead sponsor	University Hospital, Clermont-Ferrand
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	160
Start date	1 February 2018
Primary completion	1 May 2025
Estimated completion	1 February 2026
Sites	16 locations across France

Drugs / interventions tested

Collection of blood and bone marrow — full drug profile →

Conditions studied

Chronic Myeloid Leukemia (CML) — all drugs for Chronic Myeloid Leukemia (CML) →
Chronic Phase — all drugs for Chronic Phase →

Sponsor

University Hospital, Clermont-Ferrand

Who can join

18 and older, any sex, with Chronic Myeloid Leukemia (CML) or Chronic Phase. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite the use of TKIs

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer stem cells: advances in knowledge and implications for cancer therapy.
Chu X, Tian W, Ning J, Xiao G, et al · · 2024 · cited 311× · PMID 38965243 · DOI 10.1038/s41392-024-01851-y
Epigenetic Research in Stem Cell Bioengineering-Anti-Cancer Therapy, Regenerative and Reconstructive Medicine in Human Clinical Trials.
Dompe C, Janowicz K, Hutchings G, Moncrieff L, et al · · 2020 · cited 9× · PMID 32326172 · DOI 10.3390/cancers12041016

Verify or expand the search:

Other recruiting trials for Chronic Myeloid Leukemia (CML)

Currently open trials in the same condition.

NCT07165535 — Quality of Life and Care Organization of Patients With Chronic Myeloid Leukemia in the Lombardy Hematology Network · recruiting
NCT06514534 — Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi · Phase 2 · recruiting
NCT05589896 — A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantat · Phase 1, PHASE2 · recruiting
NCT03849651 — TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-ce · Phase 2 · active not recruiting
NCT02790515 — Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical · Phase 2 · active not recruiting

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03481868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
Last refreshed: 9 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03481868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing